To our knowledge, this is the first report to evaluate the efficacy and safety of re-immunotherapy with nivolumab plus ipilimumab for patients with advanced NSCLC previously treated with anti-PD-1 and/or anti-PD-L1 antibodies. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.